Chengdu Bright Eye Hospital Co. Ltd. (301239) - Total Liabilities
Based on the latest financial reports, Chengdu Bright Eye Hospital Co. Ltd. (301239) has total liabilities worth CN¥2.46 Billion CNY (≈ $360.64 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Chengdu Bright Eye Hospital Co. Ltd. cash flow conversion to assess how effectively this company generates cash.
Chengdu Bright Eye Hospital Co. Ltd. - Total Liabilities Trend (2019–2024)
This chart illustrates how Chengdu Bright Eye Hospital Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Check 301239 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Chengdu Bright Eye Hospital Co. Ltd. Competitors by Total Liabilities
The table below lists competitors of Chengdu Bright Eye Hospital Co. Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sarawak Oil Palms Bhd
KLSE:5126
|
Malaysia | RM1.28 Billion |
|
Lecron Energy Saving Materials
SHE:300343
|
China | CN¥503.63 Million |
|
Summit
TA:SMT
|
Israel | ILA5.48 Billion |
|
Rukun Raharja Tbk
JK:RAJA
|
Indonesia | Rp3.48 Trillion |
|
China West Construction Group Co Ltd
SHE:002302
|
China | CN¥24.68 Billion |
|
Anhui Huaheng Biotechnology Co. Ltd. A
SHG:688639
|
China | CN¥3.00 Billion |
|
Ulker Biskuvi Sanayi AS
IS:ULKER
|
Turkey | TL86.63 Billion |
|
Shenzhen Anche Technologies Co Ltd
SHE:300572
|
China | CN¥676.40 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Chengdu Bright Eye Hospital Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Chengdu Bright Eye Hospital Co. Ltd. (301239) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Chengdu Bright Eye Hospital Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Chengdu Bright Eye Hospital Co. Ltd. (2019–2024)
The table below shows the annual total liabilities of Chengdu Bright Eye Hospital Co. Ltd. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥2.48 Billion ≈ $362.44 Million |
-0.80% |
| 2023-12-31 | CN¥2.50 Billion ≈ $365.36 Million |
+55.13% |
| 2022-12-31 | CN¥1.61 Billion ≈ $235.51 Million |
+16.85% |
| 2021-12-31 | CN¥1.38 Billion ≈ $201.55 Million |
+12.60% |
| 2020-12-31 | CN¥1.22 Billion ≈ $178.99 Million |
+425.20% |
| 2019-12-31 | CN¥232.90 Million ≈ $34.08 Million |
-- |
About Chengdu Bright Eye Hospital Co. Ltd.
Bright Eye Hospital Group Co., Ltd., a specialized chain medical institution company, engages in the provision of ophthalmic general medical services in China. Its ophthalmology institutions provide diagnosis, treatment, health care, medical optometry, glasses, and other general ophthalmic medical services for patients with ophthalmic diseases in the areas of refractive surgery, cataract, ophthal… Read more